PubMed:21049067 JSONTXT

{"project":"PubmedHPO","denotations":[{"id":"T1","span":{"begin":141,"end":147},"obj":"HP_0002664"},{"id":"T2","span":{"begin":160,"end":173},"obj":"HP_0003002"},{"id":"T3","span":{"begin":160,"end":173},"obj":"HP_0100013"},{"id":"T4","span":{"begin":167,"end":173},"obj":"HP_0002664"},{"id":"T5","span":{"begin":235,"end":240},"obj":"HP_0002664"}],"text":"Lack of knowledge: breast cancer and the soluble interleukin-6 receptor.\nBACKGROUND: Cytokines are and may be used as therapeutic targets in cancer therapy. In breast cancer, interleukin (IL)-6 is associated with different features of tumor biology like metastasis, certain stages, and decreased survival. It is now an established fact that signaling via the soluble IL-6 receptor (sIL-6R) («transsignaling») is an important process in the IL-6 machinery.\nMETHODS AND RESULTS: In this mini-review, we discover that published knowledge about sIL-6R serum levels in breast cancer patients is sparse and, furthermore, most in vitro data merely show that tumor cells produce the sIL-6R endogenously.\nCONCLUSIONS: Therefore, a lot of research is still necessary to analyze the significance of the sIL-6R and therefore the transsignaling process in breast tumors. More knowledge about the sIL-6R in breast cancer would give insights into its putative role as blood marker of active tumor disease. Secondly, the sIL-6R may be useful in breast cancer as a new therapeutic pathway. If, as suggested by the literature, IL-6 mediates the aggressiveness and the growth of breast tumors, elevated circulating levels of IL-6 and its receptor may identify patients for whom the IL-6 complex is a therapeutic target."}

{"project":"Allie","denotations":[{"id":"SS1_21049067_3_0","span":{"begin":175,"end":186},"obj":"expanded"},{"id":"SS2_21049067_3_0","span":{"begin":188,"end":190},"obj":"abbr"},{"id":"SS1_21049067_4_0","span":{"begin":359,"end":380},"obj":"expanded"},{"id":"SS2_21049067_4_0","span":{"begin":382,"end":388},"obj":"abbr"}],"relations":[{"id":"AE1_21049067_3_0","pred":"abbreviatedTo","subj":"SS1_21049067_3_0","obj":"SS2_21049067_3_0"},{"id":"AE1_21049067_4_0","pred":"abbreviatedTo","subj":"SS1_21049067_4_0","obj":"SS2_21049067_4_0"}],"text":"Lack of knowledge: breast cancer and the soluble interleukin-6 receptor.\nBACKGROUND: Cytokines are and may be used as therapeutic targets in cancer therapy. In breast cancer, interleukin (IL)-6 is associated with different features of tumor biology like metastasis, certain stages, and decreased survival. It is now an established fact that signaling via the soluble IL-6 receptor (sIL-6R) («transsignaling») is an important process in the IL-6 machinery.\nMETHODS AND RESULTS: In this mini-review, we discover that published knowledge about sIL-6R serum levels in breast cancer patients is sparse and, furthermore, most in vitro data merely show that tumor cells produce the sIL-6R endogenously.\nCONCLUSIONS: Therefore, a lot of research is still necessary to analyze the significance of the sIL-6R and therefore the transsignaling process in breast tumors. More knowledge about the sIL-6R in breast cancer would give insights into its putative role as blood marker of active tumor disease. Secondly, the sIL-6R may be useful in breast cancer as a new therapeutic pathway. If, as suggested by the literature, IL-6 mediates the aggressiveness and the growth of breast tumors, elevated circulating levels of IL-6 and its receptor may identify patients for whom the IL-6 complex is a therapeutic target."}